![](http://apasl.info/app-def/S-102/apasl/wp-content/uploads/2018/07/APASL2015_Trevor-Hawkins-192x114.jpg)
All-Oral 12-Week Combination Treatment With Daclatasvir and Sofosbuvir in Patients Infected With HCV Genotype 3: ALLY-3 Phase 3 Study
URL | http://www.ic-hep.com/webcasts/apasl2015/THawkins/ |
---|---|
Speaker | Trevor Hawkins, MD |
![](http://apasl.info/app-def/S-102/apasl/wp-content/uploads/2018/07/APASL2015_Darrell_Crawford-192x114.jpg)
Interferon Treatment in Hepatitis C: Necessary or Not in Future Aspects?
URL | http://www.ic-hep.com/webcasts/apasl2015/DCrawford/ |
---|---|
Speaker | Darrell Crawford, MD |
![](http://apasl.info/app-def/S-102/apasl/wp-content/uploads/2018/07/APASL2015_Patrick_Marcellin-192x114.jpg)
The Differences in Antiviral Agents in the Treatment of Hepatitis B
URL | http://www.ic-hep.com/webcasts/apasl2015/PMarcellin |
---|---|
Speaker | Patrick Marcellin, MD |
![](http://apasl.info/app-def/S-102/apasl/wp-content/uploads/2018/07/APASL2015_Paul_Kwo-192x114.jpg)
The impact of the treatment of HCV in developing Hepatocellular Carcinoma
URL | http://www.ic-hep.com/webcasts/apasl2015/PKwo/ |
---|---|
Speaker | Paul Kwo, MD |
![](http://apasl.info/app-def/S-102/apasl/wp-content/uploads/2018/07/APASL2015_Wan-Long_Chuang-192x114.jpg)
The Role of New Combination Therapies without Interferon for Chronic HCV Infection
URL | http://www.ic-hep.com/webcasts/apasl2015/WChuang/ |
---|---|
Speaker | Wan-Long Chuang, MD |